Take a look at the last two decades’ worth of drug rollouts and one thing is clear: Hepatitis C has fueled some NASA-worthy blastoffs. But they're far from the only impressive launches. Pfizer, Biogen, Merck and Regeneron boast spots on two new expert analyses.Original Article
What’s beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
